FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:606-608 August 5, 2004 Number 6 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Cystic fibrosis, a progressive and ultimately fatal inherited disorder caused by a mutant cystic fibrosis transmembrane conductance regulator (CFTR) gene, has mobilized the government, charitable foundations, the biotechnology industry, and academia to work together to accelerate the development of drugs to combat the disease. The tools of molecular biology have facilitated the entry of about two dozen drugs in the developmental pipeline, any one of which, if successful, could halt the progression of the disease. As recently reported by Egan and colleagues,¹ the newest therapeutic candidate is curcumin, a so-called nutraceutical agent or dietary supplement that is a mixture of . . . [Full Text of this Article]

Source Information

From the Division of Pediatric Respiratory Sciences, Johns Hopkins School of Medicine, Baltimore.

This article has been cited by other articles:

• Murray, K. L., Lee, C. K. K., Mogayzel, P. J. Jr., Zeitlin, P. L., Rosenstein, B. J. (2008). Dietary supplement use in pediatric patients with cystic fibrosis. Am J Health Syst Pharm 65: 562-565 [Abstract] [Full Text]  
• Salvioli, S., Sikora, E., Cooper, E. L., Franceschi, C. (2007). Curcumin in Cell Death Processes: A Challenge for CAM of Age-Related Pathologies. Evid Based Complement Alternat Med 4: 181-190 [Abstract] [Full Text]  
• Grubb, B. R., Gabriel, S. E., Mengos, A., Gentzsch, M., Randell, S. H., Van Heeckeren, A. M., Knowles, M. R., Drumm, M. L., Riordan, J. R., Boucher, R. C. (2006). SERCA Pump Inhibitors Do Not Correct Biosynthetic Arrest of {Delta}F508 CFTR in Cystic Fibrosis. Am. J. Respir. Cell Mol. Bio. 34: 355-363 [Abstract] [Full Text]  
• Bengmark, S. (2006). Curcumin, An Atoxic Antioxidant and Natural NF{kappa}B, Cyclooxygenase-2, Lipooxygenase, and Inducible Nitric Oxide Synthase Inhibitor: A Shield Against Acute and Chronic Diseases. JPEN J Parenter Enteral Nutr 30: 45-51 [Abstract] [Full Text]  
• Yang, X., Thomas, D. P., Zhang, X., Culver, B. W., Alexander, B. M., Murdoch, W. J., Rao, M. N.A., Tulis, D. A., Ren, J., Sreejayan, N. (2006). Curcumin Inhibits Platelet-Derived Growth Factor-Stimulated Vascular Smooth Muscle Cell Function and Injury-Induced Neointima Formation. Arterioscler. Thromb. Vasc. Bio. 26: 85-90 [Abstract] [Full Text]  
• Rowe, S. M., Miller, S., Sorscher, E. J. (2005). Cystic Fibrosis. NEJM 352: 1992-2001 [Full Text]